Inactive Instrument

All News EntreMed Inc Nasdaq

Equities

US29382F2020

End-of-day quote Nasdaq Other stock markets
- ^USD	-

08/07	CASI Pharmaceuticals Names Daniel Lang CFO	MT
08/07	CASI Pharmaceuticals, Inc. Appoints Daniel Lang as CFO	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CASI Pharmaceuticals Names Daniel Lang CFO	08/07	MT
CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP	08/07	PR
CASI Pharmaceuticals, Inc. Appoints Daniel Lang as CFO	08/07	CI
CASI Pharmaceuticals, Inc. Appoints Daniel Lang as Senior Vice President	08/07	CI
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	27/06	MT
US Futures Trend Lower Pre-Bell as Investors Await Slew of Economic Data	27/06	MT
Top Premarket Gainers	27/06	MT
CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company	27/06	PR
CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company	27/06	CI
CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He	27/06	PR
Wei-Wu He proposed to acquire Business Operations in China and all license-in, distribution and related rights in Asia from CASI Pharmaceuticals, Inc. for $40 million.	26/06	CI
CASI Pharmaceuticals Receives Acquisition Proposal for its Entire China Business	26/06	CI
CASI Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from VR Adviser, LLC, Foresite Capital Management, LLC, Panacea Venture Management Co., Ltd.	26/06	CI
Sector Update: Health Care Stocks Advance in Afternoon Trading	15/05	MT
CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study	15/05	MT
CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)	15/05	PR
CASI Pharmaceuticals Receives FDA Clearance on the Investigational New Drug Application for CID-103 in Immune Thrombocytopenia	15/05	CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q1 Revenue $3.4M, vs. Street Est of $12M	14/05	MT
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS	14/05	PR
CASI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News EntreMed Inc Nasdaq

Equities

US29382F2020

All News

Filters